Aktuellt
SENASTE
Redeye leaves a comment following OncoZenge’s announcement yesterday of having entered into a non-binding partnership agreement with specialty pharmaceutical company Molteni Farmaceutici for commercialization of BupiZenge in Europe. We are encouraged to see that OncoZenge has managed to quickly bounce back following the recent setback and see this news as a testament to the potential of BupiZenge.
LÄS MER
